Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 16;10(8):1721.
doi: 10.3390/jcm10081721.

Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events

Leonardo De Luca  1 , Elisa Bellettini  1 , Dario Di Maio  2 , Enrico Natale  1 , Rita Lucia Putini  1 , Sabrina Anticoli  3 , Furio Colivicchi  4 , Paolo Calabrò  2 , Francesco Musumeci  5 , Domenico Gabrielli  1
Affiliations
Review

Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events

Leonardo De Luca et al. J Clin Med. .

Abstract

Stroke is the leading cause of disability and mortality worldwide. After an acute cerebrovascular ischemia, recurrent vascular events, including recurrent stroke or transient ischemic accidents (TIA), occur in around 20% of cases within the first 3 months. In order to minimize this percentage, antiplatelet therapy may play a key role in the management of non-cardioembolic cerebrovascular events. This review will focus on the current evidence of antiplatelet therapies most commonly discussed in practice guidelines and used in clinical practice for the treatment of stroke/TIA complications. The antiplatelet therapies most commonly used and discussed are as follows: aspirin, clopidogrel, and ticagrelor.

Keywords: TIA; antiplatelet therapy; aspirin; clopidogrel; stroke; ticagrelor.

PubMed Disclaimer

Conflict of interest statement

De Luca reports lecture fees from Astra-Zeneca, Bayer and Sanofi outside the submitted work; other authors do not declare any conflict of interest.

References

    1. Amarenco P., Bogousslavsky J., Caplan L.R., Donnan G.A., Wolf M.E., Hennerici M.G. The Ascod Phenotyping Of Ischemic Stroke (Updated Asco Phenotyping) Cerebrovasc. Dis. 2013;36:1–5. doi: 10.1159/000352050. - DOI - PubMed
    1. Koton S., Sang Y., Schneider A.L.C., Rosamond W.D., Gottesman R.F., Coresh J. Trends In Stroke Incidence Rates In Older Us Adults: An Update From The Atherosclerosis Risk In Communities (Aric) Cohort Study. JAMA Neurol. 2020;77:109–113. doi: 10.1001/jamaneurol.2019.3258. - DOI - PMC - PubMed
    1. Sirimarco G., Lavallée P.C., Labreuche J., Meseguer E., Cabrejo L., Guidoux C., Klein I.F., Olivot J.M., Abboud H., Adraï V., et al. Overlap Of Diseases Underlying Ischemic Stroke. The Ascod Phenotyping. Stroke. 2013;44:2427–2433. doi: 10.1161/STROKEAHA.113.001363. - DOI - PubMed
    1. Investigators N.C. Prevalence, Incidence, and Mortality of Stroke in China. Results from A Nationwide Population-Based Survey of 480,687 Adults. Circulation. 2017;135:759–771. - PubMed
    1. Johnston S.C., Amarenco P., Denison H., Evans S.R., Himmelmann A., James S., Knutsson M., Ladenvall P., Molina C.A., Wang Y., et al. Ticagrelor And Aspirin or Aspirin Alone in Acute Ischemic Stroke or Tia. N. Engl. J. Med. 2020;383:207–217. doi: 10.1056/NEJMoa1916870. - DOI - PubMed

LinkOut - more resources